Systemic Phlebotropic Drugs in Pharmacotherapy of Chronic Venous Insufficiency of the Lower Extremities

The modern aspects of pharmacotherapy of chronic venous insufficiency (CVI) of the lower extremities are presented in the article. Phlebotropic drugs are medications for basic pharmacotherapy of CVI. A common characteristic of pharmacodynamics of these drugs is the ability to increase the venous tone, and reduce severity of specific symptoms and syndromes of CVI. The efficiency of the most widespread venotonic drugs has been analyzed. The largest number of preclinical and clinical research among all groups of veno-active drugs has been devoted to the study of Micronized Purified Flavonoid Fraction (MPFF). It has been determined that the therapeutic effect of MPFF is higher compared to the therapeutic effect of non-micronised Diosmin. An important feature of the action of MPFF is a rapid onset of the venotonic effect, the effect is shown already from the first hour after administration and lasts during the day. This action is successfully complemented by improved rheological properties of the blood, reduction in blood viscosity, stimulation of the drainage function of lymphatic vessels. Treatment should be given by courses, which duration depends on disease severity, and is for 2-3 months, but not less than twice a year. The continuous therapeutic scheme can be used in the case of refractory forms of CVI. MPFF is characterized by a high clinical efficacy, high bioavailability and safety. It does not cause serious adverse reactions, well tolerated and can be used as a drug of the first choice.